文献速递脑血管病

COVID-19疫苗接种后急性动脉缺血性卒中:系统综述与Meta分析

Acute Arterial Ischemic Stroke Following COVID-19 Vaccination: A Systematic Review and Meta-analysis.
PubMed 文献 · Neurology · 2022-10-03

该系统综述与Meta分析纳入2项随机对照试验、3项队列研究和11项注册研究,共782,989,363剂COVID-19疫苗接种后17,481例急性动脉缺血性卒中(AIS)病例。任何疫苗类型接种后AIS汇总比例为每10万剂4.7例(95%CI 2.2-8.1;I²=99.9%),mRNA疫苗与腺病毒载体疫苗间无差异。接种后AIS病例中血栓性血小板减少综合征(TTS)汇总比例为3.1%(95%CI 0.7%-7.2%;I²=78.8%)。

要点

  • 任何COVID-19疫苗接种后AIS汇总比例为每10万剂4.7例(95%CI 2.2-8.1)。
  • mRNA疫苗接种后AIS比例每10万剂9.2例,腺病毒载体疫苗每10万剂2.9例,两者无差异。
  • 接种后AIS病例中TTS汇总比例为3.1%(95%CI 0.7%-7.2%)。

核心结论

  • COVID-19疫苗接种后AIS汇总比例与一般人群AIS患病率相当,远低于SARS-CoV-2感染者中AIS患病率。
  • 接种后AIS患者中TTS报告非常罕见。

研究设计与样本

  • 系统综述与Meta分析,纳入随机对照临床试验、药物警戒注册、注册研究、观察性队列和病例系列。
  • 共纳入2项随机对照试验、3项队列研究和11项注册研究,涵盖782,989,363剂COVID-19疫苗接种后17,481例AIS病例。

主要发现

  • 任何COVID-19疫苗类型接种后AIS汇总比例为每10万剂4.7例(95%CI 2.2-8.1;I²=99.9%)。
  • mRNA疫苗接种后AIS汇总比例为每10万剂9.2例(95%CI 2.5-19.3;I²=99.9%),腺病毒载体疫苗接种后为每10万剂2.9例(95%CI 0.3-7.8;I²=99.9%),两者无差异。
  • mRNA疫苗与载体疫苗接种后AIS患者的人口学特征无差异。
  • 接种后AIS病例中TTS汇总比例为3.1%(95%CI 0.7%-7.2%;I²=78.8%)。

局限性

  • 异质性I²=99.9%(AIS汇总比例及mRNA与载体疫苗比较),TTS汇总比例异质性I²=78.8%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Acute arterial ischemic stroke (AIS) has been reported as a rare adverse event following coronavirus disease 2019 (COVID-19) vaccination with messenger RNA (mRNA) or viral vector vaccines. However, data are sparse regarding the risk of postvaccination AIS and its potential association with thrombotic-thrombocytopenia syndrome (TTS). METHODS: A systematic review and meta-analysis of randomized controlled clinical trials (RCTs), pharmacovigilance registries, registry-based studies, observational cohorts, and case-series was performed with the aim to calculate the following: (1) the pooled proportion of patients presenting with AIS following COVID-19 vaccination; (2) the prevalence of AIS after mRNA and vector-based vaccination; and (3) the proportion of TTS among postvaccination AIS cases. Patient characteristics were assessed as secondary outcomes. RESULTS: Two RCTs, 3 cohort studies, and 11 registry-based studies comprising 17,481 AIS cases among 782,989,363 COVID-19 vaccinations were included in the meta-analysis. The pooled proportion of AIS following exposure to any COVID-19 vaccine type was 4.7 cases per 100,000 vaccinations (95% CI 2.2-8.1; I 2 = 99.9%). The pooled proportion of AIS following mRNA vaccination (9.2 cases per 100,000 vaccinations; 95% CI 2.5-19.3; I 2 = 99.9%) did not differ compared with adenovirus-based vaccination (2.9 cases per 100,000 vaccinations; 95% CI 0.3-7.8; I 2 = 99.9%). No differences regarding demographics were disclosed between patients with AIS following mRNA-based or vector-based vaccination. The pooled proportion of TTS among postvaccination AIS cases was 3.1% (95% CI 0.7%-7.2%; I 2 = 78.8%). DISCUSSION: The pooled proportion of AIS following COVID-19 vaccination is comparable with the prevalence of AIS in the general population and much lower than the AIS prevalence among severe acute respiratory syndrome coronavirus 2-infected patients. TTS is very uncommonly reported in patients with AIS following COVID-19 vaccination.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Stefanou MI, Palaiodimou L, Aguiar de Sousa D, et al. Acute Arterial Ischemic Stroke Following COVID-19 Vaccination: A Systematic Review and Meta-analysis. Neurology. 2022. PMID: 36002319. doi:10.1212/WNL.0000000000200996

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。